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Background: Health related quality of life (HRQoL) is an important outcome helping to understand the impact of
antiretroviral therapy (ART). We examined and compared the HRQoL in relation to ART status among HIV-infected
patients in a public sector service in Cape Town, South Africa. In addition, we aimed to examine the relationship
between ART status and HRQoL according to CD4 count strata.
Methods: A cross sectional study sample of 903 HIV-infected patients who were categorized as not receiving ART
(ART-naïve) or receiving first-line ART for > 6 months (ART). HRQoL outcomes were compared in the two groups.
HRQoL was assessed using the EQ-5D (five domains) and Visual Analogue Scale (EQ-5D VAS).
Results: Of the total sample, 435 were categorised as ART naïve (76% women) and 468 were on ART (78% women).
There were no significant associations between groups for most of the EQ-5D domains, however ART-naïve experienced
a significantly greater problem with mobility than the ART group. Being ART-naïve (adjusted odds ratio (aOR) 3.08 95%
confidence interval (CI) 1.63- 7.89) and obese 2.78 (95% CI 1.24- 6.22) were identified as predictors for increased mobility
problems in multivariate analysis. In addition, receiving ART (5.61 difference; 95% CI 2.50 - 8.72) and having some source
of income (4.76; 95% CI 1.63 -7.89) were identified as predictors for a higher EQ-5D VAS score. When grouped according
to CD4 count strata, there were no significant difference between groups for most of the EQ-5D domains, however the
ART-naïve group indicated having significantly greater problems under the CD4 count of >500 cells/μL in the
anxiety/depression domain (22.4% vs 8.8%, p = 0.018) and significantly lower EQ-5D VAS scores under the CD4 counts
of ≤200 cells/μL (median 80 (IQR 60–90) vs 90 (IQR 80–100), p = 0.0003) and 201–350 cells/μL (median 80 (IQR 70–90)
vs 90 (80–100), p = 0.0004) compared to ART group.
Conclusions: HRQoL (self-rated health state) was improved with ART use, including those with immunocompromised
status, which may be relevant to the public sector ART program in South Africa.
Keywords: Health related quality of life, HIV or AIDS, Health outcomes, EQ-5DBackground
Human immunodeficiency virus (HIV) is a global epi-
demic with 35 million people living with HIV/AIDS
worldwide, the majority of whom reside in resource-poor
countries. By 2012, sub-Saharan Africa accounted for 70%
of the universal total, with South Africa home to the* Correspondence: mweete.nglazi@gmail.com
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million) [1].
The roll out of antiretroviral therapy (ART) has pro-
foundly improved the grave portrayal of this disease in
South Africa. The national ART program commenced in
2004 and the latest WHO statistics show that, at the end
of 2012, there were an estimated 2 150 881 HIV-infected
people receiving ART in South Africa [2]. However, while
ART prolongs the lives of HIV-infected individuals [1], it
is associated with a variety of metabolic sequelae, includ-
ing metabolic abnormalities and morphological body
changes [3-5], that may adversely affect quality of life withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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understand the impact of ART use and on health-related
quality of life (HRQoL).
Numerous studies have examined HRQoL in HIV-
infected individuals the impact of ART on HRQoL in HIV
infected adults in South Africa [7-12]. These studies have
been either cross-sectional or longitudinal designs. A recent
cross-sectional study demonstrated a significant association
between ART use and improved HRQoL indicators [7]. A
second cross-sectional study found an improvement in
physical health only [8]. Another study showed less pain
and discomfort and fewer problems with self-care, daily ac-
tivities and general mobility [10]. In addition, longitudinal
studies have shown significant improvements in HRQoL
during 7 months [9], 12 months [11] and 24 months [12] of
follow-up after ART initiation.
There are, however, relatively fewer studies from South
Africa that assessed the effect of higher CD4 cell counts
on HRQoL [7,13]. Bhargava and colleagues [13] found the
HRQoL of patients receiving ART increased significantly
with improvement in CD4 count . Igumbor and colleagues
[7] found weak but significant associations between CD4
cell counts and HRQoL in a cohort of treatment-naïve pa-
tients and those who had received ART for 12 months.
Globally, there has been concern about how ART-
related toxicities may adversely affect HRQoL of HIV-
infected individuals. Non-nucleotide reverse transcriptase
inhibitors such as stavudine (d4T) have been shown to be
associated with metabolic complications such as dyslipide-
mias, lipoatrophy, peripheral neuropathy and lactic acid-
osis [14-25]. Owing to toxicity concerns, the World
Health Organization (WHO) in 2010 recommended the
replacement of d4T with tenofovir (TDF) or zidovudine
(AZT) -based first-line regimens which have better safety
profiles [26,27].
Despite the World Health Organization recommenda-
tion to phase out d4T, the national ART programs of
South Africa and other developing countries continue to
use d4T as part of their first-line ART regimen. By the
end of 2011, 1.1 million people were taking d4T regi-
mens globally, the vast majority in resource limited set-
tings in sub-Saharan Africa [28]. Progress in phasing-out
d4T has been tampered by the higher cost of the alter-
native drugs AZT and TDF, uncertainties regarding
whom to give priority to for phase out, the existence of
stockpiles of d4T in several countries [28] and the failure
of major donors to support the complete elimination of
d4T [29]. With the lack of full elimination of d4T from
first-line regimens in resource-poor countries, there is a
need for studies on the impact of d4T-containing first-
line ART regimens on HRQoL in order to inform their
national ART programs.
Therefore, the objectives of this study were to establish
whether there was a difference in the HRQoL in thosepatients who were not receiving ART compared to those
who were on first-line ART (predominantly d4T-containing
regimen for longer than 6 months) in public sector treat-
ment program in Cross roads, Cape Town, South Africa. In
addition, we aimed to examine the relationship between
ART status and HRQoL according to CD4 count strata.
Methods
Study setting and population
This study is a cross-sectional secondary analysis of a
subset of data collected from a broader study examining
the prevalence of metabolic complications of ART in
HIV-infected patients, conducted by the Division of Dia-
betic Medicine and Endocrinology of the University of
Cape Town in 2007. The study site was the Crossroads
community health clinic in Cape Town which provides
HIV care to over 5000 patients. As per national ART
guidelines at the time of data collection, adult patients
qualified for public sector ART if they had a CD4 count
below 200 cells/μL and symptomatic, and/or WHO Stage
four AIDS defining illness (World Health Organisation
HIV/AIDS Staging System) [30]. The study population
consisted of 435 not yet receiving ART (ART-naïve) and
468 on the South African National Department of Health
first-line ART regimen (stavudine (d4T) or zidovudine
(AZT), lamuvidine (3TC) and efavirenz (EFV) or nevipar-
ine (NVP). At the time of data collection, patients in South
Africa only qualified for public sector ART if they had a
CD4 count below 200 cells/μL and symptomatic, and/or
WHO Stage four AIDS defining illness (World Health
Organisation HIV/AIDS Staging System) [30].
The study cohort was selected due to the fact that d4T
is stll being used as part of first line regimens in South
Africa and other resource-limited countries [2,28] and it
is, therefore, important to determine whether the drug
has a negative impact on HRQoL.
Sampling technique
The broader study used convenient sampling technique.
Patients were conveniently sampled consecutively from
the day list at the Crossroad Community Health clinic;
and all patients meeting the inclusion criteria were in-
vited to participate in the study. Study recruitment
began in February 2007 with a target sample size of
1650 (Note that the main objectives of the original study
from which the study emanates were to estimate and
compare the prevalence of metabolic complications in
three ART regimen- hence to estimate the prevalence of
lipodystrophy at 40% (an assumption derived from the
literature) within an ART regimen with a precision of
4% a sample size of 557 per ART regimen is needed and
to compare the prevalence of lipodystrophy between the
three ART regimens using a chi-squared test with 90%
power and 5% significant level a sample size of 552 was
Nglazi et al. BMC Public Health 2014, 14:676 Page 3 of 9
http://www.biomedcentral.com/1471-2458/14/676needed per ART regimen. A total target sample size of
1650 patients (consisting of 550 per ART regimen) was
therefore needed to meet the requirements of both ob-
jectives). However, only 1035 patients (approximately
95% of patients approached) consented to participate in
the broader study.
Inclusion criteria
To participate in the broader study, subjects were
18 years and older and were required not to have chan-
ged their ART in the past six months. Exclusion criteria
included a history of diabetes mellitus or impaired glu-




Age, yrs, median (IQR) 33 (29–40)
Female 697 (77.2)
Education
No education 58 (6.4)
≤ Grade 12 820 (90.8)
>Grade 12 25 (2.8)
Housing density (persons/room), median (IQR) 2 (1–3)
Employment
Full or part time 250 (27.7)
Unemployed 648 (71.8)
Other 5 (0.6)
Current smoker 136 (15.1)
Ever drank alcohol 426 (47.2)
CD4 count, cells/μl median (IQR) 289 (184–455)
Previous TB 379 (49.8)
Treatment regimens
d4T 3TC EFV -
d4T 3TC NVP -
AZT 3TC EFV -
AZT 3TC NVP -
Other -




BMI, kg/m2, median (IQR) 25.2 (22.0 -29.6)
Waist-to-hip ratio, mean ± SD 0.85 ± 0.07
Sagittal height, cm, median (IQR) 19.3 (17.0-22.0)
Sum of skinfolds, median (IQR) 108.8 (69.5-158.7
Calf skinfolds, median (IQR) 14.6 (8.4 – 21.6)
d4T, Stavudine; AZT,.Zidovudine; 3TC, Lamuvidine; EFV, Efavirenz; NVP, Nevirapine.infections, severe diarrhoea (>6 stools/day), known renal
failure, pregnancy, or had received glucocorticoid ther-
apy within the past six months.Measurements
This study formed part of a larger study examining the
metabolic complications of ART in South African HIV-
positive patients where subjects underwent an oral glucose
tolerance test (OGTT), blood pressure measurements,
lipodystrophy questionnaire and a neuropathy examin-
ation [31]. Those data therefore will not be reported in
this paper.ART-naïve ART P value
(n = 435) (n = 468)
N (%) N (%)
32 (28–38) 35 (30–42) < 0.0001
331 (76.1) 366 (78.2) 0.450
25 (5.8) 33 (7.1) 0.654
399 (91.7) 421 (90.0)
11 (2.5) 14 (3.0)
2 (1–3) 1.5 (1–3) 0.002
115 (26.4) 135 (28.9) 0.791
317 (72.9) 331 (70.3)
3 (0.7) 2 (0.4)
75 (17.2) 61(13.0) 0.077
226 (52.0) 200 (42.8) 0.006
224 (153–437) 318 (222–468) <0.0001








24.2 (21.4-29.0) 26.0 (22.9-30.0) 0.0004
0.84 ± 0.07 0.87 ± 0.08 < 0.01
18.3 (16.5-21.0) 19.8 (17.5-22.5) <0.0001
) 103.8 (64.4-164.1) 111.5 (74.1-153.8) 0.557
15.6 (9.3-22.6) 13.4 (7.8-20.5) 0.012
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The following anthropometric measurements were done in
all subjects: weight, height, skinfolds (triceps, biceps, sub-
scapular, supra-iliac, abdominal, thigh and calf), circumfer-
ences (waist, hip, arm and thigh) and sagittal abdominal
diameter (SAD) [32,33]. All measurements were performed
by one trained investigator for consistency of data. All mea-
surements were done in duplicate as previously described
[31,34,35]. Sagittal abdominal diameter was measured as
the distance between the blades of a portable sliding-beam
caliper at the level of the iliac crest (L4-5) after a normal ex-
piration with the subject lying in the supine position on a
flat, standard, clinic examining bed.
Questionnaire
A questionnaire was administered face-to-face to all
subjects on entry into the study by trained field workers.
General and demographic information, measures of
socio-economic status, family medical history, clinical
conditions and medication, dietary intake, and the use
of drugs and toxins (including alcohol and tobacco) was
obtained from the questionnaire. A review of subjects’
clinical records was done to provide all information on
prior ART regimen, time on ART and CD4 count data.
Quality of Life
HRQoL was assessed using a validated EQ-5D (five do-
mains) tool and Visual Analogue Scale (EQ-5D VAS)
[36-38]. The EQ-5D comprises of two components- a
questionnaire and a visual analogue scale-EQ-5D VAS).




No problems 844 (93.5)
Problems 59 (6.5)
Self Care
No problems 897 (99.3)
Problems 6 (0.7)
Usual Activities
No problems 885 (98.2)
Problems 17 (1.9)
Pain/Discomfort
No problems 680 (75.3)
Problems 223 (24.7)
Depression/Anxiety
No problems 782 (86.6)
Problems 121 (13.4)
VAS score, median (IQR) 80 (70–95)health status that includes five domains regarding quality
of daily life, namely mobility, self-care, usual activities,
pain and discomfort, and anxiety and depression. Each
domain has three levels: no problems, some problems
and severe problems. The EQ-5D VAS is used to assess
overall current health. A score is recorded on a vertical,
visual analogue scale with endpoints: 0 being “worst im-
aginable health state” to 100 being “best imaginable
health state”.
Statistical Analysis
Subject characteristics and HRQoL outcomes were tabu-
lated and stratified by ART status. Proportions were
compared for categorical variables. Continuous variables
were presented as medians and interquartile ranges unless
otherwise stated. All continuous variables were not nor-
mally distributed (normality tested using Shapiro-Wilk test)
except for waist-to-hip ratio. The Wilcoxon-Rank sum
test was used to compare medians and Student’s t test
to compare means.
The effect of ART status on HRQoL was examined
using logistic regression for dichotomous outcome vari-
ables (EQ-5D five domains) and linear regression for
the continuous outcome variable (EQ-5D VAS score).
Each EQ-5D domain were categorised as “no problems”
versus “problems” because the number of subjects that
reported “severe problems” were very low, and therefore
“some and severe problems” were combined to form
one “problems” sub-category. The explanatory variable
of interest in all models was ART status. Confounding
variables were CD4 count, age, gender, educationnd ART groups
ART-naïve ART P value
N (%) N (%)
397 (91.3) 444 (95.5)
38 (8.7) 21 (4.5) 0.010
430 (98.9) 467 (99.8) 0.084
5 (1.2) 1 (0.2)
423 (97.5) 462 (98.7) 0.167
11 (2.5) 6 (1.3)
316 (72.6) 364 (77.8) 0.074
119 (27.3) 104 (22.2)
372 (85.5) 410 (87.6) 0.357
63 (14.5) 58 (12.4)
80 (70–90) 90 (80–100) <0.0001
Table 3 Multivariate analyses showing factors associated with the five Health related Quality of Life (EuroQol) domains
Mobility Selfcare Usual activities Pain/discomfort Anxiety/depression
Variable OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
ART status
ART-naïve vs ART 3.08 (1.63 - 7.89) 0.007 5.21 (0.45 - 60.27) 0.187 2.40 (0.66 - 8.75) 0.184 1.31 (0.88 - 1.95) 0.184 0.88 (0.53 - 1.89) 0.607
CD4 count, cells/μL
> 200 vs ≤ 200 1.16 (0.55 - 2.47) 0.697 2.93 (0.28- 30.40) 0.367 0.75 (0.24 - 2.37) 0.622 0.81 (0.54 - 1.21) 0.311 1.14 (0.66 - 1.95) 0.646
Age 1.02 (0.99 - 1.06) 0.242 0.92 (0.80 - 1.06) 0.236 0.95 (0.89 - 1.03) 0.208 1.01 (0.99 - 1.03) 0.471 1.01 (0.99 - 1.04) 0.320
Gender
Female vs male 0.44 (0.19 - 1.00) 0.050 1.90 (0.12 -30.97) 0.651 2.04 (0.39 - 10.77) 0.401 0.83 (0.52 - 1.31) 0.416 1.03 (0.55 - 1.91) 0.933
Education
No education 1.00 1.00 1.00 1.00 1.00 1.00
≤ Grade 12 0.37 (0.13 - 1.06) 0.065 0.028(0.002-0.309) 0.004 0.11 (0.02 - 0.58) 0.009 0.90 (0.41 - 1.94) 0.779 0.59 (0.23 - 1.51) 0.273
>Grade 12 0.41 (0.04 - 4.20) 0.450 - - 0.31 (0.02 - 4.33) 0.382 1.14 (0.31 - 4.29) 0.841 0.59 (0.10 - 3.52) 0.565
Employment
Unemployed 1.00 1.00 1.00 1.00 1.00
Full or part time or other 0.71 [0.31 - 1.59] 0.400 0.75 (0.06 - 9.54) 0.826 0.31 (0.02 - 4.33) 0.458 1.34 (0.90 - 2.00) 0.150 0.59 (0.34 - 1.04) 0.067
Previous TB 1.54 (0.72 - 3.28) 0.267 2.23 (0.25 - 19.54) 0.469 3.10 (0.85 - 11.24) 0.086 1.12 (0.75 - 1.66) 0.583 0.51 (0.30 - 0.86) 0.012
BMI category
Not obese 1.00 1.00 1.00 1.00 1.00
Obese 2.78 (1.24- 6.22) 0.013 0.92 (0.07- 11.63) 0.947 1.09 (0.27 - 4.41) 0.906 1.20 (0.77 -1.86) 0.427 1.27 (0.74 - 2.17) 0.384



















Table 4 Multivariate analyses showing factors associated
with Visual Analogue Scale score
Variable Coefficient 95% CI p-value
ART status
ART vs ART-naïve 5.61 2.50 - 8.72 <0.001
CD4 count, cells/μL
>200 vs ≤200 0.58 −2.63 - 3.79 0.724
Age −0.034 −0.20 - 0.13 0.682
Gender
Female vs male 0.66 −2.95 - 4.26 0.720
Education
No education 1.00 1.00
≤ Grade 12 0.21 −6.07 - 6.48 0.949
>Grade 12 −5.12 −15.33 - 5.09 0.325
Employment
Unemployed 1.00 1.00
Full or part time or other 4.76 1.63-7.89 0.003
Housing density
<1.9 1.00 1.00
≥ 2 1.76 −1.15 - 4.66 0.236
Previous TB −2.09 −5.20 - 1.01 0.186
BMI category
Not obese 1.00 1.00
Obese 3.10 −0.38 - 6.57 0.081
Constant 82.04022, R-squared 0.0616, Root MSE 16.106.
All differences were significant at P < 0.05.
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drank alcohol, previous TB, and BMI category.
The relationship between ART status and HRQoL ac-
cording to CD4 count strata was examined using Chi-
squared test for dichotomous outcome variables (EQ-5D
five domains) and one-way analysis of variance by ranks
(Kruskal-Wallis test) with alpha/(k(k-1)) adjustments for
multiple comparisons for the continuous outcome vari-
able (EQ-5D VAS score). The CD4 count strata were
categorized as ≤200 cells/μL, and 201–350 cells/μL,
351–500 cells/μL and >500 cells/μL according to the re-
cent WHO recommendations and national guidelines
for commencing ART [30,39,40].
All analyses were performed using STATA 11.1 (Stata-
Corp, College Station, Texas, USA). The level of signifi-
cance for the one-way analysis of variance by ranks
(Kruskal-Wallis test) was set at adjusted P = 0.0009.
However, the level of significance for the other tests was
set at P <0.05. 95% confidence intervals were also calcu-
lated throughout.
Ethical approval
The study was approved by the Research Ethics Committee
of the Faculty of Health Sciences of the University of Cape
Town. Prior to participation in the study, risks and proce-
dures were explained to the subjects, all of whom provided
informed consent to participate in the study. The data used




The sociodemographic and clinical characteristics, as well
as body composition of the participants are presented in
Table 1. There were a total of 903 participants (435 were
ART- naïve and 468 were on ART). Participants in the
ART group were significantly older than in the ART-naive
group (median 32 years (IQR 28 – 38) years vs median
35 years (IQR 30–42 years; P < 0.0001). Three times as
many women as men in both groups participated in the
study (78% vs 22% ART, 76% vs 24% ART-naive). Both
groups were similar for level of education and employment
status. The ART-naive group differed significantly from the
ART group in terms of housing density P = 0.002). A higher
proportion of patients reported drinking alcohol in the
ART group compared to the ART-naïve group (52% vs
43%; p = 0.006), but smoking rates did not differ.
The ART group had higher CD4 counts and less cases
with a previous history of TB compared to the ART-
naive group (P < 0.0001 and P < 0.001, respectively). The
most common treatment regimen of the subjects on
antiretroviral therapy was d4T/3TC/EFV (37%). The me-
dian period on a d4T-containing regimen among the
ART group was 13 months (IQR 8–20 months) and onan AZT-containing regimen was 12 months (IQR 7–
18.5 months).
Measures of body composition showed significant
differences between the groups, however, the sum of skin-
folds was not different. Subjects in the ART group weighed
significantly more (P = 0.0004), had a higher mean BMI
(P < 0.01), greater mean waist-to-hip ratio (P < 0.0001)
and greater median sagittal height (P < 0.0001).
Comparison of Health related quality of Life Outcomes by
ART status
The HRQoL outcomes did not differ between groups for
self-care, usual activities, pain/discomfort and anxiety/
depression (Table 2). The ART-naïve group, however, ex-
perienced a significantly greater problem with mobility
than the ART group (9 vs 4%, P < 0.05). Multivariate
analysis showed no significant differences between
groups for self-care, usual activities, pain/discomfort and
anxiety/depression (Table 3). In contrast, those in the
ART-naive group were 3.08 times more likely to report
problems with mobility than those in the ART group
(95% CI 1.37 - 6.94). In addition, those obese were 2.78
times more likely to have increased mobility problems
than those not obese (95% CI 1.24- 6.22).
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(IQR 70–90), which was lower than that of the ART group
(median 90, IQR 80–100; P < 0.0001). Multivariate ana-
lyses showed a 5.61 point increases in VAS score in the
ART group compared to ART-naïve group (95% CI 2.50 -
8.72; p < 0.001 (Table 4). Also, those with some source of
income were 4.76 times more likely to have a higher EQ-
5D VAS score than those unemployed (95% CI 1.63 -7.89).
Comparison of Health related quality of Life Outcomes by
ART status according to CD4 count strata
When grouped according to CD4 count strata, there

































>500 80 (70–90)ART groups in most of the EQ-5D domains (Table 5).
However, the ART-naïve group indicated having signifi-
cantly greater problems under the CD4 count of >500
cells/μL in the anxiety/depression domain (22.4% vs 8.8%,
p = 0.018) and significantly lower EQ-5D VAS scores
under the CD4 counts of ≤200 cells/μL (median 80 (IQR
60–90) vs 90 (IQR 80–100), p = 0.0003) and 201–350
cells/μL (median 80 (IQR 70–90) vs 90 (80–100).
Discussion
In this study that compared HRQoL outcomes between
ART-naïve and patients on ART for 6 months or longer
(who were mostly using a d4T-based first-line regimen)s (%) and median EQ VAS score by ART status across CD4
ART-naïve ART P value
N (%) N (%)
14 (8.6) 2 (2.9) 0.113
6 (6.0) 7 (5.0) 0.736
3 (4.7) 3 (3.3) 0.649
10 (13.2) 6 (7.5) 0.244
1(0.61) 0 (0.0) 0.511
1 (1.0) 0 (0.0) 0.236
0 (0.0) 1 (1.1) 0.403
3 (4.0) 0 (0.0) 0.073
6 (3.7) 0 (0.0) 0.104
2 (2.0) 2 (1,4) 0.733
0 (0.0) 2 (2.0) 0.235
3 (4.0) 1 (1.3) 0.281
50 (30.7) 18 (25.7) 0.445
27 (27.0) 26 (18.6) 0.121
12 (18.8) 22 (23.9) 0.442
22 (29.0) 20 (25.0) 0.578
22 (13.5) 10 (14.3) 0.873
10 (10.0) 23 (16.4) 0.154
7 (10.9) 11 (12.0) 0.845
17 (22.4) 7 (8.8) 0.018
80 (60–90) 90 (80–100) 0.0003
80 (70–90) 90 (80–100) 0.0004
82.5 (80–100) 90 (77.5-100) 0.455
80 (70–90) 90 (80–100) 0.004
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senting the subject’s self-rated health state) improved
significantly on ART; and when subjects were grouped
according to their baseline CD4 counts, EQ-VAS scores
were significantly lower in ART-naïve patients with CD4
counts ≤200 cells/μL and 201–350 cells/μL.
Our finding that study subject’s EQ-5D VAS scores
improved significantly on ART, suggests that drug toxic-
ities, especially those related to d4T have little impact on
subects self-rated health. This study, therefore, support
the findings of several studies [9-12] which report im-
proved HRQoL outcomes on ART, despite participants
being national first-line regimens containing d4T with
known toxicities [14-25]. The study by Pitt and col-
leagues [9], for example, showed that drug toxicities,
mainly those related to d4T, had little impact on mental
health HRQoL scores during the first 48 weeks on ART.
We also found that, when subjects were grouped ac-
cording to their baseline CD4 counts, EQ-VAS scores
were significantly lower in ART-naïve patients with CD4
counts ≤200 cells/μL and 201–350 cells/μL. Our study
findings corroborate recently reported studies. Mathews
and colleagues found that EQ-5D VAS score improved
with increasing CD4 cell count strata and were 65.4, 70
and 75 for CD4 counts <50, 50–199 and ≥200 cells/μL
[41]. Anis and colleagues [42] showed that improve-
ments in CD4 cell counts were associated with higher
HRQoL scores (P = 0.08). Bhargava and colleagues [13]
found the HRQoL of patients receiving ART increased
significantly with improvement in CD4 count. Igumbor
and colleagues [7] found weak but significant associa-
tions between CD4 cell counts and HRQoL in a cohort
of treatment-naïve patients and those who had received
ART for 12 months.
The strength of this study was the large sample size of
HIV-infected individuals derived from a primary care clinic
and it is one of the few studies that shed light on the impact
of higher CD4 cell counts on HRQoL. However, the results
of the study may only be generalizable to the study popula-
tion and other similar settings. Our finding that the EQ-5D
VAS was sensitive to ART use and ART eligibility (based
on CD4 cell count) supports the use of this particular in-
strument in future assessments of HRQoL outcomes
among HIV infected individuals in South Africa.
The study had the several limitations. Because this was a
non-randomized study, the associations observed in the
study are potentially biased due to residual confounding.
We could not adjust for HIV-related symptom burden,
duration on ART (among those on ART) and HIV-RNA
viral load levels because all these factors known to influ-
ence HRQoL among HIV infected individuals [38] were
not assessed in the present study. Furthermore, there may
be limitations to the generalizability of study findings due
to the CD4 count categories used in this study.Conclusions
In conclusion, the study data suggest that ART is effect-
ive in improving the HRQoL (that is, self-rated health
state), including those subjects who were immunocom-
promised, which may be applicable to ART eligibility of
the public sector ART program in South Africa. Further
research is needed to examine the impact that long term
ART use has on the HRQoL of HIV-infected people, as
well as looking at long term government strategies to
improve HIV-infected patient’s general health perception
during the course of lifelong ART.
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